The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 7, 2017, Pages 1196-1207

  Reich, K ^a   Puig, L ^b   Mallbris, L ^c   Zhang, L ^c   Osuntokun, O ^c   Leonardi, C ^d  

^a SCIderm Clinical Research and Dermatologikum   (Germany)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c ELI LILLY AND COMPANY   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; IXEKIZUMAB; PLACEBO; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CELLULITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION STUDY; FEMALE; HUMAN; INFLUENZA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SKIN CANDIDIASIS; SUBCUTANEOUS IMMUNOTHERAPY; THRUSH; TONSILLITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VAGINA CANDIDIASIS; VERY ELDERLY; ADOLESCENT; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PSORIASIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY WEIGHT; CLINICAL TRIALS, PHASE III AS TOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; ETANERCEPT; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 85018743344     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.14252     Document Type: Article

References (7)

1. Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314–320.
2. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2: e54.
3. Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007–1011.
4. Liu L, Lu J, Allan BW et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 2016; 9: 39–50.
5. Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375: 345–356.
6. Griffiths CE, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541–551.
7. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888–898.